Loading...
•
Jun 30, 2020
TG Therapeutics Q2 2020 Earnings Report
TG Therapeutics reported financial results for the second quarter ended June 30, 2020 and recent company developments.
Key Takeaways
TG Therapeutics announced positive progress in 2020, including the completion of the NDA rolling submission for umbralisib and positive topline data from the UNITY-CLL Phase 3 trial. With a strong cash balance, the company is positioned to execute milestones and transition into a commercial organization.
Completed the NDA rolling submission for umbralisib in previously treated Marginal Zone Lymphoma and Follicular Lymphoma.
Reported positive topline data from the UNITY-CLL Phase 3 trial.
Maintained a healthy balance sheet with over $275 million in cash.
Looking forward to reporting topline data from the Phase 3 ULTIMATE program in Multiple Sclerosis.
TG Therapeutics
TG Therapeutics
Forward Guidance
TG Therapeutics anticipates an impactful end of year and into 2021, with several key objectives for the remainder of 2020 and early 2021.